A new study validates the Sybil AI model for predicting lung cancer risk using low-dose CT in a predominantly Black cohort at an urban safety-net hospital.
Key Details
- 1Study presented at the 2025 IASLC World Conference on Lung Cancer.
- 2Validation conducted at UI Health on 2,092 baseline low-dose CT scans from 2014-2024.
- 3Cohort primarily Non-Hispanic Black (62%), with 13% Hispanic and 4% Asian.
- 4Sybil demonstrated strong Area Under the Curve (AUC): 0.94 (1 yr), 0.90 (2 yr), 0.86 (3 yr), 0.85 (4 yr), 0.80 (5 yr), 0.79 (6 yr).
- 5Results remained strong after restricting to Black participants and excluding recent diagnoses.
- 6The Sybil Implementation Consortium will advance to prospective clinical trials for clinical workflow integration.
Why It Matters
Demonstrating reliable AI performance in racially and socioeconomically diverse settings is crucial for equitable lung cancer screening. This validation may facilitate broader adoption and help address longstanding disparities in lung cancer outcomes.
Source
EurekAlert
Related News
•EurekAlert
AI-Driven CT Tool Predicts Cancer Spread in Oropharyngeal Tumors
Researchers have created an AI tool that uses CT imaging to predict the spread risk of oropharyngeal cancer, offering improved treatment stratification.
•EurekAlert
AI-Driven CT Imaging Predicts Cardiac Events in Large UK Cohort
An AI tool analyzing CCTA images can predict future cardiovascular events and death in patients with suspected stable coronary artery disease.
•EurekAlert
AI Multimodal Models Improve Breast Cancer Recurrence Risk Prediction
Initial results from an ECOG-ACRIN and Caris Life Sciences collaboration show AI-driven multimodal models can more accurately predict recurrence risk in early-stage breast cancer.